Bangkok, Thailand (April 18, 2013) –  Besins Healthcare (Besins) and Shin Nippon Biomedical Laboratories (SNBL), a global leader in hormonal products, announced today that they have completed a licensing agreement to use SNBL’s proprietary intranasal drug delivery system, μco™ System (muco system), to further develop its BHR-310 investigational agent containing progesterone for treating mild traumatic brain injury (TBI).

Published in the April 2013 edition of Lab Animal, SNBL USA's IACUC Administrator discusses training on reporting animal welfare concerns.

With an increasing number of biotherapeutics coming through to market, and the growing need for non-invasive self-administration options for patients to use in the home setting, nasal drug delivery provides a promising approach. Here, Dr Shunji Haruta, PhD, Executive Officer, SNBL, Ltd and General Manager, NDS Division, describes how the company’s nasal powder delivery technology, μcoTM System, can meet these requirements.